These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 24517375)
1. A novel p38 MAPK docking-groove-targeted compound is a potent inhibitor of inflammatory hyperalgesia. Willemen HL; Campos PM; Lucas E; Morreale A; Gil-Redondo R; Agut J; González FV; Ramos P; Heijnen C; Mayor F; Kavelaars A; Murga C Biochem J; 2014 May; 459(3):427-39. PubMed ID: 24517375 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of N-cyclopropylbenzamide-benzophenone hybrids as novel and selective p38 mitogen activated protein kinase (MAPK) inhibitors. Heo J; Shin H; Lee J; Kim T; Inn KS; Kim NJ Bioorg Med Chem Lett; 2015 Sep; 25(17):3694-8. PubMed ID: 26115577 [TBL] [Abstract][Full Text] [Related]
3. Repurposing mosloflavone/5,6,7-trimethoxyflavone-resveratrol hybrids: Discovery of novel p38-α MAPK inhibitors as potent interceptors of macrophage-dependent production of proinflammatory mediators. Hassan AHE; Yoo SY; Lee KW; Yoon YM; Ryu HW; Jeong Y; Shin JS; Kang SY; Kim SY; Lee HH; Park BY; Lee KT; Lee YS Eur J Med Chem; 2019 Oct; 180():253-267. PubMed ID: 31310917 [TBL] [Abstract][Full Text] [Related]
4. Synthesis, evaluation and docking of novel pyrazolo pyrimidines as potent p38α MAP kinase inhibitors with improved anti-inflammatory, ulcerogenic and TNF-α inhibitory properties. Somakala K; Tariq S; Amir M Bioorg Chem; 2019 Jun; 87():550-559. PubMed ID: 30928877 [TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory effect and selectivity profile of AS1940477, a novel and potent p38 mitogen-activated protein kinase inhibitor. Terajima M; Inoue T; Magari K; Yamazaki H; Higashi Y; Mizuhara H Eur J Pharmacol; 2013 Jan; 698(1-3):455-62. PubMed ID: 23183108 [TBL] [Abstract][Full Text] [Related]
6. Microglial/macrophage GRK2 determines duration of peripheral IL-1beta-induced hyperalgesia: contribution of spinal cord CX3CR1, p38 and IL-1 signaling. Willemen HLDM; Eijkelkamp N; Wang H; Dantzer R; Dorn GW; Kelley KW; Heijnen CJ; Kavelaars A Pain; 2010 Sep; 150(3):550-560. PubMed ID: 20609517 [TBL] [Abstract][Full Text] [Related]
7. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation. Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877 [TBL] [Abstract][Full Text] [Related]
8. Substituted Benzamides from Anti-inflammatory and p38 Kinase Inhibitors to Antitubercular Activity: Design, Synthesis and Screening. Kulkarni R; Mitkari U; Achaiah G; Laufer S; Bikshapti DVRN; Chandrashekar VM; Gurav PB; Joshi SJ; Chipade VD Mini Rev Med Chem; 2018; 18(17):1486-1497. PubMed ID: 28685700 [TBL] [Abstract][Full Text] [Related]
9. DBM1285 suppresses tumor necrosis factor alpha production by blocking p38 mitogen-activated protein kinase/mitogen-activated protein kinase-activated protein kinase 2 signaling pathway. Kang JS; Kim HM; Choi IY; Han SB; Yoon YD; Lee H; Park KH; Cho IJ; Lee CW; Lee K; Lee KH; Park SK J Pharmacol Exp Ther; 2010 Aug; 334(2):657-64. PubMed ID: 20427474 [TBL] [Abstract][Full Text] [Related]
10. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity. Hill RJ; Dabbagh K; Phippard D; Li C; Suttmann RT; Welch M; Papp E; Song KW; Chang KC; Leaffer D; Kim YN; Roberts RT; Zabka TS; Aud D; Dal Porto J; Manning AM; Peng SL; Goldstein DM; Wong BR J Pharmacol Exp Ther; 2008 Dec; 327(3):610-9. PubMed ID: 18776065 [TBL] [Abstract][Full Text] [Related]
11. Docking, synthesis and pharmacological activity of novel urea-derivatives designed as p38 MAPK inhibitors. de Oliveira Lopes R; Romeiro NC; de Lima CK; Louback da Silva L; de Miranda AL; Nascimento PG; Cunha FQ; Barreiro EJ; Lima LM Eur J Med Chem; 2012 Aug; 54():264-71. PubMed ID: 22647219 [TBL] [Abstract][Full Text] [Related]
12. MicroRNA-124 as a novel treatment for persistent hyperalgesia. Willemen HL; Huo XJ; Mao-Ying QL; Zijlstra J; Heijnen CJ; Kavelaars A J Neuroinflammation; 2012 Jun; 9():143. PubMed ID: 22731384 [TBL] [Abstract][Full Text] [Related]
13. Blockade of peripheral P2Y1 receptors prevents the induction of thermal hyperalgesia via modulation of TRPV1 expression in carrageenan-induced inflammatory pain rats: involvement of p38 MAPK phosphorylation in DRGs. Kwon SG; Roh DH; Yoon SY; Moon JY; Choi SR; Choi HS; Kang SY; Han HJ; Beitz AJ; Lee JH Neuropharmacology; 2014 Apr; 79():368-79. PubMed ID: 24333674 [TBL] [Abstract][Full Text] [Related]
14. GRK2: a novel cell-specific regulator of severity and duration of inflammatory pain. Eijkelkamp N; Heijnen CJ; Willemen HL; Deumens R; Joosten EA; Kleibeuker W; den Hartog IJ; van Velthoven CT; Nijboer C; Nassar MA; Dorn GW; Wood JN; Kavelaars A J Neurosci; 2010 Feb; 30(6):2138-49. PubMed ID: 20147541 [TBL] [Abstract][Full Text] [Related]
15. Structure-based design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine-based p38 MAP kinase inhibitors. Kaieda A; Takahashi M; Takai T; Goto M; Miyazaki T; Hori Y; Unno S; Kawamoto T; Tanaka T; Itono S; Takagi T; Hamada T; Shirasaki M; Okada K; Snell G; Bragstad K; Sang BC; Uchikawa O; Miwatashi S Bioorg Med Chem; 2018 Feb; 26(3):647-660. PubMed ID: 29291937 [TBL] [Abstract][Full Text] [Related]
16. Peripheral and central p38 MAPK mediates capsaicin-induced hyperalgesia. Sweitzer SM; Peters MC; Ma JY; Kerr I; Mangadu R; Chakravarty S; Dugar S; Medicherla S; Protter AA; Yeomans DC Pain; 2004 Oct; 111(3):278-285. PubMed ID: 15363871 [TBL] [Abstract][Full Text] [Related]
17. Clonidine, an alpha-2 adrenoceptor agonist relieves mechanical allodynia in oxaliplatin-induced neuropathic mice; potentiation by spinal p38 MAPK inhibition without motor dysfunction and hypotension. Yeo JH; Yoon SY; Kim SJ; Oh SB; Lee JH; Beitz AJ; Roh DH Int J Cancer; 2016 May; 138(10):2466-76. PubMed ID: 26704560 [TBL] [Abstract][Full Text] [Related]
18. Synthesis, p38α MAP kinase inhibition, anti-inflammatory activity, and molecular docking studies of 1,2,4-triazole-based benzothiazole-2-amines. Tariq S; Alam O; Amir M Arch Pharm (Weinheim); 2018 Apr; 351(3-4):e1700304. PubMed ID: 29611883 [TBL] [Abstract][Full Text] [Related]
19. Anti-inflammatory activity of 4-methoxyhonokiol is a function of the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via NF-kappaB, JNK and p38 MAPK inactivation. Zhou HY; Shin EM; Guo LY; Youn UJ; Bae K; Kang SS; Zou LB; Kim YS Eur J Pharmacol; 2008 May; 586(1-3):340-9. PubMed ID: 18378223 [TBL] [Abstract][Full Text] [Related]
20. Improved potency of pyridin-2(1H)one derivatives for the treatment of mechanical allodynia. Visseq A; Descheemaeker A; Hérault K; Giraud F; Abrunhosa-Thomas I; Artola A; Anizon F; Dallel R; Moreau P Eur J Med Chem; 2021 Dec; 225():113748. PubMed ID: 34392191 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]